Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo

By Vigushin D.   Mirsaidi N.   Brooke G.   Sun C.   Pace P.   Inman L.   Moody C.   Coombes R.  

Medical Oncology, Vol. 21, Iss. 1, 2004-03 ,pp. : 21-30

Humana Press, Inc

Access to resources Recommend Favorite

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

By Karp Judith E   Lancet Jeffrey E  

Future Oncology, Vol. 1, Iss. 6, 2005-12 ,pp. : 719-731

Future Medicine

Access to resources Recommend Favorite

The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy

By Cheung K.L.  

Breast Cancer Research and Treatment, Vol. 67, Iss. 3, 2001-06 ,pp. : 273-278

Springer Publishing Company

Access to resources Recommend Favorite

Comments on the use of a single or multiple probe-set approach for microarray-based analyses of routine molecular markers in breast cancer

By Coradini Danila  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 647-651

Springer Publishing Company

Access to resources Recommend Favorite

Molecular markers for targeted neoadjuvant rectal cancer therapy

By Gantt Gerald A   Kalady Matthew F  

Colorectal Cancer, Vol. 2, Iss. 4, 2013-08 ,pp. : 321-331

Future Medicine

Access to resources Recommend Favorite